This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies?
by Ahan Chakraborty
Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the competitive landscape forward.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia
by Zacks Equity Research
Teva files an NDA seeking FDA approval for its once-monthly olanzapine LAI for the treatment of adults with schizophrenia.
SNYPositive Net Change TEVAPositive Net Change ANIPPositive Net Change CSTLNegative Net Change
medical
Implied Volatility Surging for Prestige Consumer Stock Options
by Zacks Equity Research
Investors need to pay close attention to PBH stock based on the movements in the options market lately.
PBHNegative Net Change
medical
Here's Why You Should Add Cencora Stock to Your Portfolio Now
by Zacks Equity Research
Cencora's U.S. Healthcare Solutions strength, RCA gains, and raised FY25 guidance underscore its accelerating growth momentum.
ISRGNegative Net Change CORPositive Net Change VCYTNegative Net Change MEDPPositive Net Change
medical medical-devices
Is it Worth Retaining NEOG Stock in Your Portfolio for Now?
by Zacks Equity Research
Neogen leans on new product launches and 3M Food Safety integration to offset solvency strains and macro pressures.
OMCLNegative Net Change ILMNPositive Net Change NEOGPositive Net Change BTSGPositive Net Change
medical medical-devices
Phibro Animal Health Stock Climbs 59.6% YTD: What's Driving It?
by Zacks Equity Research
PAHC's 59% YTD surge rides on strong Animal Health momentum, booming vaccines and global gains despite the rising competition.
OMCLNegative Net Change ILMNPositive Net Change PAHCPositive Net Change BTSGPositive Net Change
medical medical-devices
Reasons to Retain TransMedics Stock in Your Portfolio for Now
by Zacks Equity Research
TMDX gains momentum as OCS technology, a robust pipeline and strong Q3 results fuel growth, though gross margin pressure tempers the outlook.
BSXNegative Net Change ISRGNegative Net Change MEDPPositive Net Change TMDXNegative Net Change
medical medical-devices
Cronos Group Plans Strategic Europe Expansion: How to Play the Stock?
by Sundeep Ganoria
CRON's planned CanAdelaar acquisition boosts its push into the Dutch adult-use cannabis market and highlights its strengthening international momentum.
CRONPositive Net Change TLRYPositive Net Change ACBPositive Net Change
marijuana medical
Is TEM Stock a Buy, Hold, or Sell During Its Pivotal Transition?
by Sridatri Sarkar
Tempus AI's shift toward scalable revenues, high-margin data services and broader AI capabilities defines a pivotal moment for TEM investors.
VEEVPositive Net Change HIMSNegative Net Change TEMNegative Net Change
medical
Do Options Traders Know Something About CERT Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Certara stock based on the movements in the options market lately.
CERTNegative Net Change
medical
Community Health Systems Stock Falls 7% Amid Debt & Other Pressures
by Zacks Equity Research
Shares of CYH decline 7%. Heavy debt, soft patient volumes and ongoing investor concerns keep pressure on the hospital operator.
LHPositive Net Change UHSPositive Net Change CYHNegative Net Change
medical
Hims & Hers Plunges 29.1% in 6 Months: Time to Hold the Stock or Sell?
by Debanjana Dey
HIMS expands into Canada and Europe while facing regulatory hurdles and execution risks in weight-loss care.
TDOCNegative Net Change GDRXNo Net Change HIMSNegative Net Change
medical medical-devices
Is Tempus AI Stock a Buy Now or a Hold After a Big 2025 Run?
by Urmimala Biswas
Tempus AI rallies in 2025, but a Hold rank and mixed style scores argue for patience until pricing, FDA, and MRD milestones firm up.
IQVPositive Net Change GHNegative Net Change TEMNegative Net Change
artificial-intelligence earnings-report healthcare medical medical-devices valuation
GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron
by Zacks Equity Research
Structure Therapeutics jumps after phase II data show aleniglipron delivering strong, durable weight-loss results across multiple studies.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Is the Options Market Predicting a Spike in Avantor Stock?
by Zacks Equity Research
Investors need to pay close attention to AVTR stock based on the movements in the options market lately.
AVTRNegative Net Change
medical
Is the Options Market Predicting a Spike in Aveanna Healthcare Stock?
by Zacks Equity Research
Investors need to pay close attention to AVAH stock based on the movements in the options market lately.
AVAHPositive Net Change
medical
Can Flex's Cash Flow & Market Strength Offset Ongoing Macro Pressures?
by Shreya Majumder
Flex enters the second half of fiscal 2026 with rising AI demand, strong cash flow and expanding data center momentum despite competitive and macro pressures.
JBLPositive Net Change FLEXNegative Net Change SANMPositive Net Change
artificial-intelligence automation autonomous-vehicles business-services cloud-computing medical tech-stocks
ALGN Stock Rises on Thailand Launch of Invisalign With MAOB
by Zacks Equity Research
Align Technology's Thailand debut of Invisalign with MAOB lifts shares and expands its Class II treatment options for increasing patients.
ALGNNegative Net Change OMCLNegative Net Change ILMNPositive Net Change BTSGPositive Net Change
medical
CARL Launches Aprevo Cervical Platform for Personalized Spine Surgery
by Zacks Equity Research
Carlsmed launches personalized aprevo cervical platform with early cases and new reimbursement support driving momentum in spine surgery.
ISRGNegative Net Change MEDPPositive Net Change CARLPositive Net Change
medical medical-devices
Here's Why You Should Retain OPKO Health Stock in Your Portfolio Now
by Zacks Equity Research
OPK leans on RAYALDEE momentum and strategic partnerships as pipeline trials advance, though reliance on its lone U.S. drug adds risk.
BSXNegative Net Change ISRGNegative Net Change OPKPositive Net Change MEDPPositive Net Change
medical medical-devices
Reasons to Hold Tandem Diabetes Stock in Your Portfolio for Now
by Zacks Equity Research
TNDM's global expansion and strategic integrations fuel growth potential, even as pump reliance and macro pressures weigh on performance.
OMCLNegative Net Change ILMNPositive Net Change TNDMNegative Net Change BTSGPositive Net Change
medical
RMD Stock Set to Gain From FDA Clearance of AI-Enabled Smart Comfort
by Zacks Equity Research
Resmed gains FDA's nod for Smart Comfort, an AI-driven CPAP tool boosting sleep therapy personalization and adherence.
OMCLNegative Net Change ILMNPositive Net Change RMDPositive Net Change BTSGPositive Net Change
medical medical-devices
Best Growth Stocks to Buy for December 9th
by Zacks Equity Research
SANM, ALL and PAHC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 9, 2025
ALLPositive Net Change SANMPositive Net Change PAHCPositive Net Change
construction finance medical
New Strong Sell Stocks for December 9th
by Zacks Equity Research
BRBR, AZTA and BRDCY have been added to the Zacks Rank #5 (Strong Sell) List on December 9, 2025.
BRDCYPositive Net Change BRBRNegative Net Change AZTAPositive Net Change
auto-tires-trucks consumer-staples medical
Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?
by Ekta Bagri
Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.
BIIBNegative Net Change BMYNegative Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals